Therapeutic and preventive effects of an epidermal growth factor receptor inhibitor on oral squamous cell carcinoma

Related Experiment Video

Updated: May 22, 2026

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma
12:03

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Published on: July 25, 2011

H Ge1, H Liu, Z Fu

  • 1Department of Oral Medicine, Capital Medical University, School of Stomatology, Beijing, China.

The Journal of International Medical Research
|May 23, 2012
PubMed
Abstract

Insights

The EGFR inhibitor PD153035 shows promise for treating and preventing oral squamous cell carcinoma (OSCC). This compound effectively inhibited OSCC cell growth and tumor development in preclinical models.

Area of Science:

  • Oncology
  • Cancer Research
  • Molecular Biology

Background:

  • Oral squamous cell carcinoma (OSCC) is a prevalent global cancer.
  • Epidermal growth factor receptor (EGFR) is overexpressed in OSCC and is a therapeutic target.
  • Targeting EGFR is a strategy for OSCC treatment and prevention.

Purpose of the Study:

  • To investigate the therapeutic and preventive potential of the EGFR inhibitor PD153035 against OSCC.
  • To evaluate the efficacy of PD153035 in various preclinical models of OSCC.

Main Methods:

  • In vitro studies using human OSCC cell lines.
  • In vivo studies using athymic nude mouse xenograft models.
  • In vivo studies using a 7,12-dimethyl benz[a]anthracene (DMBA)-induced hamster cheek pouch tumor model.

Main Results:

  • PD153035 inhibited OSCC cell growth, cell cycle progression, and induced apoptosis in vitro.
  • PD153035 demonstrated dose-dependent inhibition of xenograft tumor growth in mice.
  • PD153035 prevented OSCC development in hamsters and reduced proliferation and phosphorylated EGFR/STAT3 levels.

Conclusions:

  • EGFR inhibitors, including PD153035, hold significant potential for OSCC treatment.
  • PD153035 exhibits both therapeutic and preventive effects against OSCC.
  • Targeting EGFR signaling pathways is a viable strategy for combating OSCC.

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...